Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosa

Vista sencilla de ítem
dc.contributor.authorMunita, Jose M.
dc.contributor.authorAitken, Samuel L.
dc.contributor.authorMiller, William R.
dc.contributor.authorPerez, Federico
dc.contributor.authorRosa, Rossana
dc.contributor.authorShimose, Luis A.
dc.contributor.authorLichtenberger, Paola N.
dc.contributor.authorAbbo, Lilian M.
dc.contributor.authorJain, Rupali
dc.contributor.authorNigo, Masayuki
dc.contributor.authorWanger, Audrey
dc.contributor.authorAraos, Rafael
dc.contributor.authorTran, Truc T.
dc.contributor.authorAdachi, Javier
dc.contributor.authorRakita, Robert
dc.contributor.authorShelburne, Samuel
dc.contributor.authorBonomo, Robert A.
dc.contributor.authorArias, Cesar A.
dc.date.accessioned2020-08-05T13:34:42Z
dc.date.available2020-08-05T13:34:42Z
dc.description.abstractenglishA multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1093/cid/cix014
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1537-6591
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3679
dc.language.isoeng
dc.publisherOxford University Pressspa
dc.publisher.journalClinical Infectious Diseasesspa
dc.relation.ispartofseriesClinical Infectious Diseases, 1537-6591, Vol. 65, Nro. 1, 2017, p. 158–161spa
dc.relation.urihttps://academic.oup.com/cid/article/65/1/158/3069333
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2017-03-14
dc.rights.localAcceso abiertospa
dc.subject.keywordsCeftolozanespa
dc.subject.keywordsCarbapenem resistantspa
dc.subject.keywordsP. aeruginosaspa
dc.subject.keywordsMultidrug resistantspa
dc.titleMulticenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosaspa
dc.title.translatedMulticenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosaspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Munita, Jose M..pdf
Tamaño:
148.66 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos